Express News | CHEMOMAB Granted U.S. Patent #12018074: Anti CCL24 (Eotaxin2) Antibodies for Use in the Treatment of Hepatic Diseases
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $7
Roth MKM analyst Jason Wittes maintains $Chemomab Therapeutics(CMMB.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 50.5% and
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Maxim Group analyst Michael Okunewitch maintains $Chemomab Therapeutics(CMMB.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of
Express News | Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its Ccl24-Neutralizing Antibody Cm-101 in Primary Sclerosing Cholangitis
Express News | Chemomab Therapeutics Shares Are Trading Lower. The Company Announced That It Presented Two Scientific Posters Supporting the Clinical Rationale for the Company's Primary Sclerosing Cholangitis Program at EASL 2024
Express News | Chemomab Says It Presented Two Scientific Posters Supporting The Clinical Rationale For Company's Primary Sclerosing Cholangitis Program At EASL 2024, For The Study Of Liver
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
Express News | Chemomab Therapeutics Ltd : Maxim Group Initiates Coverage With Buy Rating; Target Price $4
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 GAAP EPS Results
Express News | Chemomab Therapeutics Q1 2024 GAAP EPS $(0.28) Up From $(0.80) YoY
Express News | Chemomab Therapeutics Ltd - Existing Liquidity Resources as of March 31, 2024 Will Enable It to Fund Its Operations Through March 31, 2025
Chemomab Therapeutics 1Q EPS 1.4c >CMMB
Chemomab Therapeutics 1Q EPS 1.4c >CMMB
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics Receives Nasdaq Extension
Express News | Chemomab Therapeutics Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
Express News | Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
12 Health Care Stocks Moving In Monday's Intraday Session
GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc
No Data